Atea Pharmaceuticals Inc (NAS:AVIR)
$ 4.02 0.13 (3.34%) Market Cap: 339.38 Mil Enterprise Value: -171.79 Mil PE Ratio: 0 PB Ratio: 0.71 GF Score: 43/100

Q1 2022 Atea Pharmaceuticals Inc Earnings Call Transcript

May 10, 2022 / 12:00PM GMT
Release Date Price: $5.86 (+9.94%)
Operator

Good morning, and welcome to the Atea Pharmaceuticals First Quarter 2022 Earnings Conference Call. (Operator Instructions) Please be advised that today's call is being recorded. I will now turn the call over to Jonae Barnes, Senior Vice President of Investor Relations and Corporate Communications at Atea Pharmaceuticals. Thank you. You may begin.

Jonae R. Barnes
Atea Pharmaceuticals, Inc. - SVP of IR & Corporate Communications

Good morning, everyone, and welcome to Atea Pharmaceuticals First Quarter 2022 Financial Results Conference Call. This morning, we issued a press release which outlines the topics we plan to discuss, including newly released data for bemnifosbuvir for the treatment of COVID-19. You can access the press release as well as the slides that we'll be reviewing today by going to the Investors section of our website at ir.ateapharma.com.

With me today from Atea are Chief Executive Officer and Founder; Dr. Jean-Pierre Sommadossi; Chief Development Officer, Dr. Janet Hammond; Chief Financial Officer and Executive Vice President of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot